Expert Interview
Investigating the Cross-Regimen Analysis from the HEALEY ALS Platform Trial of CNM-Au8 in patients with ALS.
Ticker(s): CLNNInstitution: University of Vermont
- Professor Department of Neurological Sciences at the University of Vermont
- Currently manages 85 patients with ALS and and is familiar with literature on AMX0035.
- Areas of interest include clinical management of neuromuscular diseases, novel therapeutic approaches to amyotrophic lateral sclerosis (ALS), clinical trials and new drug development in neuropathies.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
